Cas:874289-30-2 (4-(Dimethylcarbamoyl)-2-fluorophenyl)boronic acid manufacturer & supplier

Chemical Name:(4-(Dimethylcarbamoyl)-2-fluorophenyl)boronic acid

CAS.NO:874289-30-2

Synonyms:[4-(Dimethylcarbamoyl)-2-fluorophenyl]boronic acid;Boronic acid, B-[4-[(dimethylamino)carbonyl]-2-fluorophenyl]-

Molecular Formula:C₉H₁₁BFNO₃

Molecular Weight:210.998

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:416.5±55.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.536

PSA:60.77000

Exact Mass:211.081604

LogP:0.06

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like [4-(Dimethylcarbamoyl)-2-fluorophenyl]boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Boronic acid, B-[4-[(dimethylamino)carbonyl]-2-fluorophenyl]- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Boronic acid, B-[4-[(dimethylamino)carbonyl]-2-fluorophenyl]- Use and application,Boronic acid, B-[4-[(dimethylamino)carbonyl]-2-fluorophenyl]- technical grade,usp/ep/jp grade.

Related News: Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms. (4-(Dimethylcarbamoyl)-2-fluorophenyl)boronic acid manufacturer Inceptua is a pharmaceutical company and service partner spanning throughout the product lifecycle �C from comparator sourcing for clinical trials, through early access programs to licensing and commercialization for products. (4-(Dimethylcarbamoyl)-2-fluorophenyl)boronic acid supplier Same as Imbruvica’s original monotherapy use, the Venclexta combo offers a convenient oral treatment, while the drug’s two other approved cocktails—with Gazyva or Roche’s Rituxan—involve infusions. (4-(Dimethylcarbamoyl)-2-fluorophenyl)boronic acid vendor According to statistics, in 2017, China’s total production of chemical drugs reached 3.478 million tons, a year-on-year increase of 1.6%. The main business income showed a steady increase, from 328.972 billion yuan in 2012 to 573.475 billion yuan in 2017. The total profit was 48.644 billion yuan, but profit margins remain low (8.48% in 2017). (4-(Dimethylcarbamoyl)-2-fluorophenyl)boronic acid factory Same as Imbruvica’s original monotherapy use, the Venclexta combo offers a convenient oral treatment, while the drug’s two other approved cocktails—with Gazyva or Roche’s Rituxan—involve infusions.